A5069417803- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- CNS Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Viral-associated cancers and disorders
- SARS-CoV-2 and COVID-19 Research
- Inflammasome and immune disorders
- Multiple Myeloma Research and Treatments
- Cytomegalovirus and herpesvirus research
- Kawasaki Disease and Coronary Complications
- Medical Imaging Techniques and Applications
- T-cell and B-cell Immunology
- Respiratory Support and Mechanisms
- Aortic Disease and Treatment Approaches
- COVID-19 and healthcare impacts
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Viral Infections and Immunology Research
- Cutaneous lymphoproliferative disorders research
- Vitamin D Research Studies
Saarland University
2016-2025
University Medical Center
2023
Universitätsklinikum des Saarlandes
2019-2022
As a consequence of the continued Covid-19 lockdown in Germany, in-hospital teaching for medical students was impossible. While lectures and other theoretical training were relatively easily converted into online sessions using platforms such as Moodle, Zoom Microsoft Teams, this not case practical skills clinical interventions, bronchoscopy or colonoscopy. This study describes workaround that implemented at Saarland University Hospital utilizing virtual reality equipment to convey...
Patients with pre-existing comorbidities and immunosuppression are at greater risk for SARS-CoV-2 infection severe manifestations of COVID-19. This also includes cancer patients, who shown to have a poor prognosis after infection. Here, we describe the case 72-year old male patient B-cell depletion maintenance treatment rituximab non-Hodgkin-lymphoma had prolonged COVID-19 course initial false negative test results. Our highlights diagnostic pitfalls in diagnosing depleted patients discuss...
Abstract Background Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) resemble a continuum of rare, polygenic IL-1β-driven unknown etiology. Objective In the present study we sought to investigate potential role recently described autoantibodies neutralizing interleukin-1(IL-1)-receptor antagonist (IL-1-Ra) in pathogenesis disease. Methods Serum or plasma samples from patients (AOSD, n = 23; sJIA, 40) autoimmune and/or inflammatory controls ( 478) were...
Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies available to determine whether initial by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB).
UNFOLDER (NCT00278408, EUDRACT 2005-005218-19) is a phase-3 trial in patients with aggressive B-cell lymphoma and intermediate prognosis, including primary mediastinal (PMBCL). In 2 × factorial design, were randomized to 6× R-CHOP-14 or R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prediso(lo)ne) consolidation radiotherapy extralymphatic/bulky disease observation. Response was assessed according the standardized criteria from 1999, which did not include F-18...
B-cell-depleting therapies are increasingly being used to treat autoimmune diseases. Although thousands of patients and have been treated with these agents, the data not yet strong enough identify rare side effects certainty. We report case a patient undergoing ocrelizumab therapy for relapsing multiple sclerosis who developed severe limbic syndrome. Autoimmune pathogenesis was initially suspected, worsening on immunosuppressive therapy. Later, after diagnosis an enterovirus infection,...
Abstract Bispecific T‐cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, GPRC5DxCD3 BTCE, has shown promising results MonumenTAL‐1 trial and was recently approved by Food Drug Administration European Medicines Agency. However, under real‐world conditions may not patient characteristics clinical trials with restricted enrollment criteria. We performed retrospective analysis including 138 RRMM patients treated...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a expressing functional B-cell receptors (BCR). Recently, we described dual stimulation model of IgD+ cells by Moraxella catarrhalis antigen RpoC and its superantigen MID/hag, associated with extralong CDR3 HLA-DRB1*04 or HLADRB1* 07 haplotype. The aim the present study was to extend screening further bacteria viruses. fragment antibody-binding (Fab) regions seven new 15 previously reported cases were analyzed. reactivity...
UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18–60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index (aaIPI) 0 bulky disease (≥7.5 cm) or aaIPI 1. In a 2 × factorial design were randomized to 6× R-CHOP-14 R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prediso[lo]ne) consolidation radiotherapy extralymphatic observation. Response was...
Profound knowledge exists about the clinical, morphologic, genomic, and transcriptomic characteristics of most lymphoma entities. However, information is currently lacking on dynamic behavior malignant lymphomas. This pilot study aimed to gain insight into motility lymphomas bystander cells in 20 human lymph nodes. Generally, B were faster under reactive conditions compared with In contrast, PD1-positive T did not show systematic differences velocity between neoplastic general. could be...
The pathogenesis of autoimmune complications triggered by SARS-CoV2 has not been completely elucidated. Here, we performed an analysis the cellular immune status, cell ratios, and monocyte populations patients with COVID-19 treated in intensive care unit (ICU) (cohort 1, N = 23) normal (NCU) 2, n 10) compared control groups: ICU for noninfectious reasons 3, 30) NCU infections other than 4, 21). Patients cohort 1 presented significant differences comparison cohorts, including reduced...
It has been suggested that B-cell receptor (BCRs) stimulation by specific antigens plays a pathogenic role in diffuse large lymphoma (DLBCL). Here, it was the aim to screen for reactivities of DLBCL-BCRs spectrum autoantigens and infectious origin. Arsenite resistance protein 2 (Ars2) identified as BCR target 3/5 ABC-type DLBCL cell lines 2/11 primary cases. Compared controls, Ars2 hypo-phosphorylated exclusively cases with Ars2-specific BCRs. In validation cohort, found 8/31 ABC-type, but...